Emotion regulation and pain catastrophizing influenced pain severity and interference in patients taking opioid medications for chronic noncancer pain.
Investorideas.com ( a go-to investing platform covering cannabis stocks releases an industry snapshot looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, ...
(NASDAQ: GNLN) has entered the battle against dangerous drugs, but not only against opioids. Greenlane announced this week its plans to launch an all-new line of fentanyl, xylazine and drink spike ...
The Global non-opioid pain relief device market, which was valued at US$ 5,444.8 million in 2023, is expected to reach US$ 11,440.6 million by 2032, signaling a significant growth trajectory at a CAGR ...